GlobeNewsWire · KYMR · November 20, 2026
Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026

Get the app for more
Explore stock news, insights and company research.
Get the app → Source: GlobeNewsWire ↗